Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | BCR | P11274 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5681041 | 0.82 | ABL1 (0.60) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL11096265 | 0.81 | ABL1 (0.58) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL18255789 | 0.80 | SYK (0.48) | ABL1ABCB1BCRAPPPBRM1 | |
| SCHEMBL54542 | 0.79 | ABL1 (0.52) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL23364935 | 0.78 | ABL1 (0.50) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL6267998 | 0.78 | ABL1 (0.50) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL3794694 | 0.78 | NPC1 (0.51) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL2032366 | 0.78 | ABL1 (0.50) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL19357316 | 0.78 | CA12 (0.55) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL1974122 | 0.77 | ABL1 (0.46) | ABL1ABCB1BCRHDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092382-A1 | Modified Nucleic Acid Probes | AFFYMETRIX, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7794943-B2 | Modified nucleic acid probes | AFFYMETRIX, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090286690-A1 | Modified Nucleic Acid Probes | AFFYMETRIX, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7375198-B2 | Modified nucleic acid probes | AFFYMETRIX, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20060110727-A9 | Modified nucleic acid probes | AFFYMETRIX, INC. | 2006-05-25 | — | — | US | disclosed |
| EP-0742287-B1 | Modified nucleic acid probes | MCGALL GLENN H (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040072202-A1 | Modified nucleic acid probes | AFFYMETRIX, INC. | 2004-04-15 | — | — | US | disclosed |
| US-6156501-A | Arrays of modified nucleic acid probes and methods of use | AFFYMETRIX, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0742287-A2 | Modified nucleic acid probes | McGall, Glenn H. (US) | 1996-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060110727-A9 | Modified nucleic acid probes | ADAR, RNGTT, POLM | ABL1 2294/4885ABCB1 2940/4885BCR 1225/4885 |
| US-20040072202-A1 | Modified nucleic acid probes | ADAR, RNGTT, POLM | ABL1 2294/4885ABCB1 2940/4885BCR 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.